Engineering targeted viral vectors for gene therapy
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
To achieve therapeutic success, transfer vehicles for gene therapy must be capable of transducing target cells while avoiding impact on non-target cells. Despite the high transduction efficiency of viral vectors, their tropism frequently does not match the therapeutic need. In the past, this lack of appropriate targeting allowed only partial exploitation of the great potential of gene therapy. Substantial progress in modifying viral vectors using diverse techniques now allows targeting to many cell types in vitro. Although important challenges remain for in vivo applications, the first clinical trials with targeted vectors have already begun to take place.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
The biotin-(strept)avidin system: principles and applications in biotechnology
Diamandis, E. P., & Christopoulos, T. K. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.5.625 · Cited by 747
Three-dimensional tissue culture models in cancer biology
Kim, J. B. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.05.002 · Cited by 613
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Altering the Tropism of Lentiviral Vectors through Pseudotyping
Cronin, J., Zhang, X.-Y., & Reiser, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054546224 · Cited by 536
Bomsel, M. (1997) · Nature Medicine · doi:10.1038/nm0197-42 · Cited by 507
Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity
Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z.-Y., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7478-7491.2005 · Cited by 427
Gene therapy clinical trials worldwide 1989–2004—an overview
Edelstein, M. L., Abedi, M. R., Wixon, J., & Edelstein, R. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.619 · Cited by 350
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
“Similar to the adenovirus, pre-existing immunity to HSV infection is prevalent within the general population; however, HSV vectors are largely able to evade inactivation by host immune response.(68,69,84,85,87) HSV vector genomes also remain episomal like those of AdVs.”
BackgroundmRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Delivery technologies for genome editing
Yin, H., Kauffman, K. J., & Anderson, D. G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.280 · Cited by 597
Brown, B. D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C., & Naldini, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1372 · Cited by 556
Targeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
Li, J., Zheng, C., Cansiz, S., Wu, C., Xu, J., Cui, C., Liu, Y., Hou, W., Wang, Y., Zhang, L., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/ja512293f · Cited by 499
A vector-free microfluidic platform for intracellular delivery
Sharei, A., Zoldan, J., Adamo, A., Sim, W. Y., Cho, N., Jackson, E., Mao, S., Schneider, S., Han, M.-J., Lytton-Jean, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218705110 · Cited by 496
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Streptavidin–biotin technology: improvements and innovations in chemical and biological applications
Dundas, C. M., Demonte, D., & Park, S. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5232-z · Cited by 467
Dasari Shareena, T. P., McShan, D., Dasmahapatra, A. K., & Tchounwou, P. B. (2018) · Nano-Micro Letters · doi:10.1007/s40820-018-0206-4 · Cited by 414
Exosomes: Vehicles for the Transfer of Toxic Proteins Associated with Neurodegenerative Diseases?
Bellingham, S. A., Guo, B. B., Coleman, B. M., & Hill, A. F. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00124 · Cited by 412
Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles
Schlich, M., Palomba, R., Costabile, G., Mizrahy, S., Pannuzzo, M., Peer, D., & Decuzzi, P. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10213 · Cited by 387
Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications
Shim, M. S., & Kwon, Y. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.018 · Cited by 384
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
“Viral vectors have been engineered to deliver one or more antigens of choice, and the ability to load a relatively large genome offers the promise of developing a large variety of vaccines [306].”
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
SiRNA delivery with exosome nanoparticles.
van den Boorn, J. G., Schlee, M., Coch, C., & Hartmann, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.1830 · Cited by 361
Viral vectors: from virology to transgene expression
Bouard, D., Alazard‐Dany, N., & Cosset, F. (2009) · British Journal of Pharmacology · doi:10.1038/bjp.2008.349 · Cited by 360
Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential
Escors, D., & Breckpot, K. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0063-4 · Cited by 344
Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications
Brown, B. D., & Naldini, L. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2628 · Cited by 336
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Applications of viral nanoparticles in medicine
Yildiz, I., Shukla, S., & Steinmetz, N. F. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.04.020 · Cited by 299
Stem and progenitor cell-mediated tumor selective gene therapy
Aboody, K. S., Najbauer, J., & Danks, M. K. (2008) · Gene Therapy · doi:10.1038/gt.2008.41 · Cited by 270
Viral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269
Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery
Parodi, A., Molinaro, R., Sushnitha, M., Evangelopoulos, M., Martinez, J. O., Arrighetti, N., Corbo, C., & Tasciotti, E. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.020 · Cited by 266
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
High-throughput 5’ UTR engineering for enhanced protein production in non-viral gene therapies
Cao, J., Novoa, E. M., Zhang, Z., Chen, W. C. W., Liu, D., Choi, G. C. G., Wong, A. S. L., Wehrspaun, C., Kellis, M., & Lu, T. K. (2021) · Nature Communications · doi:10.1038/s41467-021-24436-7 · Cited by 159
POxylation as an alternative stealth coating for biomedical applications
Bludau, H., Czapar, A. E., Pitek, A. S., Shukla, S., Jordan, R., & Steinmetz, N. F. (2017) · European Polymer Journal · doi:10.1016/j.eurpolymj.2016.10.041 · Cited by 112
Involvement of long noncoding RNAs in diseases affecting the central nervous system
Pastori, C., & Wahlestedt, C. (2012) · RNA Biology · doi:10.4161/rna.20482 · Cited by 100
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“However, many other potential technologies have been developed alongside, including exosomes/liposomes, antisense oligonucleotides (AONs), electroporation of naked DNA/RNA, or application of nanoparticles [12,13].”
BackgroundMicroRNAs and the Regulation of Vector Tropism
Kelly, E. J., & Russell, S. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.288 · Cited by 82
Self-citationsiRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo
Suzuki, Y., Hyodo, K., Tanaka, Y., & Ishihara, H. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.024 · Cited by 71
Delivery technologies for in utero gene therapy
Palanki, R., Peranteau, W. H., & Mitchell, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.002 · Cited by 64
Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors
Iyer, A. K., Duan, Z., & Amiji, M. M. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500024p · Cited by 55
(2023) · doi:10.3390/vaccines11050919 · Cited by 50
Bacteriophage-Mediated Cancer Gene Therapy
Petrov, G., Dymova, M., & Richter, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214245 · Cited by 38
“However, the systemic administration of these vectors is accompanied by a decrease in the selectivity of delivery, in connection with the wide tropism of eukaryotic viruses to the cells and tissues of host organisms, the absorption of their particles by the liver and the reticuloendothelial system of the body and the…”
BackgroundNovel siRNA delivery strategy: a new "strand" in CNS translational medicine?
Gherardini, L., Bardi, G., Gennaro, M., & Pizzorusso, T. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1310-8 · Cited by 28
Metadata
- Authors
- Waehler, R., Russell, S. J., & Curiel, D. T.
- Venue
- Nature Reviews Genetics
- Published
- 2007-07-03
- Volume
- 8
- Issue
- 8
- Pages
- 573-587
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W1988177186
- Cited by
- 687
- References
- 120
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.